Evolus, Inc. (NASDAQ:EOLS) CMO Sells $60,147.36 in Stock

Evolus, Inc. (NASDAQ:EOLS) CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the transaction, the chief marketing officer now directly owns 95,671 shares of the company’s stock, valued at $1,268,597.46. This represents a 4.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Evolus Trading Down 1.6 %

Evolus stock opened at $13.25 on Friday. Evolus, Inc. has a one year low of $9.25 and a one year high of $17.82. The company’s fifty day moving average price is $13.36 and its two-hundred day moving average price is $13.91. The company has a market capitalization of $842.53 million, a price-to-earnings ratio of -14.56 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. KBC Group NV bought a new stake in Evolus during the fourth quarter worth approximately $49,000. IFP Advisors Inc boosted its holdings in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Evolus in the 4th quarter valued at $106,000. Rafferty Asset Management LLC bought a new position in Evolus in the 4th quarter worth $115,000. Finally, Quantbot Technologies LP acquired a new position in Evolus during the 4th quarter worth $118,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EOLS. Barclays upped their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Evolus in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.